Brief: Chemomab Therapeutics Says Data Supporting Role Of Co's Novel Therapeutic Target Ccl24 In Systemic Sclerosis Presented At Eular 2022
02/06/2022 12:20
June 2 (Reuters) - Chemomab Therapeutics Ltd CMMB.O :
* DATA SUPPORTING ROLE OF CHEMOMAB'S NOVEL THERAPEUTIC
TARGET
CCL24 IN SYSTEMIC SCLEROSIS PRESENTED AT EULAR 2022
* CHEMOMAB THERAPEUTICS LTD - CHEMOMAB'S CCL24-NEUTRALIZING
ANTIBODY CM-101 IS EXPECTED TO ENTER A PHASE 2 TRIAL IN SYSTEMIC
SCLEROSIS IN LATE 2022
Source text for Eikon: ID:nPn8ZB2wKa
Further company coverage: CMMB.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update